<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04890431</url>
  </required_header>
  <id_info>
    <org_study_id>OXYSED</org_study_id>
    <nct_id>NCT04890431</nct_id>
  </id_info>
  <brief_title>Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome</brief_title>
  <official_title>Impact of Oxygen Therapy on Fatigue in Patients With Hypermobile-type Ehlers-Danlos Syndrome: a Randomised Double-blind Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital St. Joseph, Marseille, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital St. Joseph, Marseille, France</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of the OXYSED study is that the delivery of 3 months of oxygen therapy via an&#xD;
      oxygen concentrator would reduce fatigue, pain, headaches, kinesiophobia, drug intake,&#xD;
      dyspnea, and improve walking performance, quality of sleep and quality of life of patients&#xD;
      with Ehlers Danlos syndrome hypermobility type (EDS / HT).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FSS (Fatigue Severity Scale) score</measure>
    <time_frame>7 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>FSS (Fatigue Severity Scale) score</measure>
    <time_frame>10 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>PRISM (Pictorial Representation of Illness and Self Measure) score</measure>
    <time_frame>7 and 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 quality of life questionnaire (Short Form Heath Survey) score</measure>
    <time_frame>7 and 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TSK (Tampa Scale Kinesiophobia) score</measure>
    <time_frame>7 and 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>walk test results</measure>
    <time_frame>7 and 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIT-6 (Headache Impact Test) score</measure>
    <time_frame>7 and 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NQ (Nijmegen questionnaire ) score</measure>
    <time_frame>7 and 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epworth Sleepiness score</measure>
    <time_frame>7 and 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSQI (Pittsburgh sleep quality index) score</measure>
    <time_frame>7 and 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS (Hospital Anxiety and Depression Scale) score</measure>
    <time_frame>7 and 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA (New Year Heart Association) score</measure>
    <time_frame>7 and 10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>consumption of care</measure>
    <time_frame>7 and 10 months</time_frame>
    <description>The consumption of care is defined by the presence of at least one major criterion associated or not with the minor criterion:&#xD;
Major criteria:&#xD;
Variation of at least one level in the frequency of use and / or in the duration of use compared to the baseline assessment concerning the use of flexible and / or rigid orthoses,&#xD;
Variation of at least one level of the analgesic levels used compared to the baseline assessment for pain relievers.&#xD;
Variation of at least one level in frequency compared to the baseline assessment for physiotherapy sessions.&#xD;
Minor criterion:&#xD;
Variation of the total daily dose compared to the baseline assessment for painkillers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of oxygen therapy sessions followed by the patient</measure>
    <time_frame>7 and 10 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Ehlers-Danlos Syndrome</condition>
  <arm_group>
    <arm_group_label>Oxygen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen</intervention_name>
    <description>oxygen treatment (5 L/minute for 30 minutes by nasal cannula, twice/day)</description>
    <arm_group_label>Oxygen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>ambient air not enriched with oxygen (5 L/minute for 30 minutes by nasal cannula, twice/day)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged ≥ 18 years;&#xD;
&#xD;
          -  Diagnosed with EDS/HT defined by the New York critieria;&#xD;
&#xD;
          -  With intense fatigue defined by an FSS ≥ 4;&#xD;
&#xD;
          -  Having given free and informed written consent;&#xD;
&#xD;
          -  Speaking french language;&#xD;
&#xD;
          -  Being affiliated with or benefiting from a social security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  with progressive parenchymal pulmonary pathology (pulmonary fibrosis, post-smoking&#xD;
             emphysema);&#xD;
&#xD;
          -  having an ongoing pregnancy or breastfeeding;&#xD;
&#xD;
          -  who have already received oxygen therapy for the EDS / HT indication in the last 6&#xD;
             months;&#xD;
&#xD;
          -  having a pathology that causes fatigue, which is not compensated or treated;&#xD;
             non-exhaustive list anemia, sleep apnea syndrome, psychiatric pathologies including&#xD;
             severe depression, organ failure (cardiac, renal, respiratory, hepatic),&#xD;
             endocrinopathies (hypo or hyperthyroidism, diabetes), nutritional deficiencies;&#xD;
&#xD;
          -  Subject to a measure for the protection of justice.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cécile Bielmann</last_name>
    <phone>04 88 73 10 70</phone>
    <phone_ext>0033</phone_ext>
    <email>cbielmann@hopital-saint-joseph.fr</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 6, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ehlers-Danlos Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

